Epilepsy trials recruiting in Illinois

All Epilepsy trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
  NCT05419492 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · Illinois: Chicago
• A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
  NCT07019922 · Phase: Phase 3 · Ages: 1 Day to 18 Years · Sex: All (male and female) · Illinois: Chicago
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  NCT06872125 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago
• A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
  NCT06422923 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  NCT06660394 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
  NCT05716100 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Springfield
• A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
  NCT04462770 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Illinois: Chicago
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
  NCT06132893 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago, Elgin
• A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
  NCT05667142 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Illinois: Springfield
• An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
  NCT05066217 · Phase: Phase 3 · Ages: 2 Years to 55 Years · Sex: All (male and female) · Illinois: Chicago
• Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
  NCT05374824 · Phase: Not specified · Ages: Up to 26 Years · Sex: All (male and female) · Illinois: Chicago
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  NCT05104983 · Phase: Phase 2 · Ages: 1 Day to 6 Months · Sex: All (male and female) · Illinois: Chicago
• Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
  NCT07594119 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
  NCT05135091 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago